Centre Hospitalier Universitaire (Chu) de Bordeaux - Groupe Hospitalier Pellegrin

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	NCT ID
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo	NonSegmental Vitiligo	Recruiting	Phase 3	2026-10-09	NCT06804811
A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease	Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, Cerebral Small Vessel Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Fabry disease, Lipid Metabolism Disorders, Lipid Metabolism, Inborn Errors, Lysosomal Storage Diseases, Nervous System, Nutritional and Metabolic Diseases, X-linked disease, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, hereditary disease, inborn errors of metabolism, lysosomal lipid storage disorder, lysosomal storage disease, metabolic disease, nervous system disorder, sphingolipidosis, vascular disorder	Recruiting	Phase 2 / Phase 3	2026-08-10	NCT06328608
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA)	autonomic nervous system disorder, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, multiple system atrophy, nervous system disorder, neurodegenerative disease, primary dysautonomia, synucleinopathy	Active, not recruiting	Phase 3	2026-07-14	NCT06706622

Clinical trials